Bukwang Pharm’s Ozanex lands in major general hospitals

Bukwang ‘s topical antibiotic

topical antibiotic that quickly reduces initial contagiousness and has low resistance

Bukwang Pharm announced that its new topical antibiotic Ozanex cream(ozenoxacin)’ recently passed the drug committee of Seoul St.Mary’s Hospital and can be prescribed in major general hospitals in Korea.

 

Ozanex, a topical antibiotic that Bukwang was first to introduce to Korea, is currently being prescribed at various major general hospitals nationwide including Seoul St.Mary’s Hospital, Samsung Medical Center, Seoul National University Hospital, Sinchon Severance Hospital, Asan Medical Center, Hanyang University Hospital, Korea University Hospital, Chonnam National University Hospital, and Kyungpook National University Hospital.

 

Ozanex was approved by the U.S.

 

FDA in December 2017 and newly released in Korea in December last year it is a prescription drug that is effective against staphylococcus aureus(S.

 

aureus) and Streptococcus pyogenes(S.

 

pyogenes), the main causes of infectious skin diseases, and is indicated for the short-tem topical treatment of impetigo in patients aged 2 months and older1.

 

For infectious skin diseases, topical antibiotics need to be used for an appropriate period at an appropriate dose according to an expert's accurate diagnosis and prescription to reduce the development of resistance and provide effective treatment.

 

According to Professor Jung-Soo Kim of the Department of Dermatology at Hanyang University Guri Hospital, “Topical antibiotics that can treat impetigo include ozenoxacin and mupirocin.

 

Ozenoxacin is a new non-fluorinated quinolone antibiotic that offers improved resistance and safety.

 

Staphylococcus aureus and Streptococcus pyogenes are the most common cause of various skin infectious diseases, including impetigo.

 

Oozenoxacin demonstrated bactericidal activity against these two strains.

 

In particular, in a large-scale clinical study that involved patients with impetigo, the bacterial culture test showed bacteriological eradication as early as day 3 of treatment, with a negative conversion rate of 87%.

 

Based on such results, HCPs expect the drug will effectively reduce the contagiousness of impetigo in the early stages.

 

A Bukwang Phamr official said, “Ozanex will settle as a new option for infectious skin diseases including impetigo.

 

We expect Bukwang’s various skin disease treatments to support HCPS and their treatment practices in Korea.”